Baktiar Hasan
Combined Military Hospital(PK)S:t Eriks Ögonsjukhus(SE)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, Lymphoma Diagnosis and Treatment, Cutaneous lymphoproliferative disorders research
Most-Cited Works
- → Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954(2010)709 cited
- → Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report(2019)284 cited
- → Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial(2010)240 cited
- → Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10(2007)219 cited
- → A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)(2011)119 cited
- → New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response(2014)115 cited
- → Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis(2016)111 cited
- → Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012(2012)103 cited
- → The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613(2017)96 cited
- → Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00(2012)93 cited